The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics.
about
Applications of CYP450 testing in the clinical settingJapanese experience with milnacipran, the first serotonin and norepinephrine reuptake inhibitor in JapanInterethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individualsIn vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6Update on the Genetic Polymorphisms of Drug-Metabolizing Enzymes in Antiepileptic Drug Therapy.Inherent abnormalities in energy metabolism in Alzheimer disease. Interaction with cerebrovascular compromise.Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin.Drug interactions with clinafloxacin.The 'apparent clearance' of free phenytoin in elderly vs. younger adultsAntiepileptic drug interactions.The importance of drug interactions in epilepsy therapy.Drug-gene interactions: inherent variability in drug maintenance dose requirementsPharmacogenetic diagnostics of cytochrome P450 polymorphisms in clinical drug development and in drug treatment.Clinical implications of drug interactions with coxibs.Pharmacogenetics and antiepileptic drugs.Toxicological interactions between alcohol and benzodiazepines.Chiral chromatographic resolution of antiepileptic drugs and their metabolites: a challenge from the optimization to the application.Implications of pharmacogenetics for individualizing drug treatment and for study design.Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population.Allele and genotype frequencies of CYP2C9 in a Korean population.Frequencies of CYP2C9 polymorphisms in North Indian population and their association with drug levels in children on phenytoin monotherapy.Population pharmacokinetics of phenytoin after intravenous administration of fosphenytoin sodium in pediatric patients, adult patients, and healthy volunteers.Epilepsy pharmacogenetics.From evidence based medicine to mechanism based medicine. Reviewing the role of pharmacogenetics.Cytochrome P450 polymorphisms and drug-induced interstitial lung disease.Development of individualized medicine for epilepsy based on genetic information.CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects.Allele and genotype frequencies of genes relevant to anti-epileptic drug therapy in Mexican-Mestizo healthy volunteers.The role of genetics and ethnicity in epilepsy management.Biomarkers for antiepileptic drug response.CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy.Role of CYP2C9, CYP2C19 and EPHX Polymorphism in the Pharmacokinetic of Phenytoin: A Study on Uruguayan Caucasian Subjects.Genetic profile of patients with epilepsy on first-line antiepileptic drugs and potential directions for personalized treatment.The association between BsmI polymorphism and bone mineral density in young patients with epilepsy who are taking phenytoin.The effect of genetic polymorphisms of cytochrome P450 CYP2C9, CYP2C19, and CYP2D6 on drug-resistant epilepsy in Turkish children.Quantitative prediction of the impact of drug interactions and genetic polymorphisms on cytochrome P450 2C9 substrate exposure.CYP2C9 polymorphism in patients with epilepsy: genotypic frequency analyzes and phenytoin adverse reactions correlation.Role of stereoselective assays in bioequivalence studies of racemic drugs: have we reached a consensus?Effect of CYP2C19 genetic polymorphism on pharmacokinetics of phenytoin and phenobarbital in Japanese epileptic patients using Non-linear Mixed Effects Model approach.Use of multi-dose activated charcoal in phenytoin toxicity secondary to genetic polymorphism.
P2860
Q24621760-C38DABBD-50EF-4547-A5ED-CC2E23FA9AFDQ24658320-AE4FB370-0667-4EFA-8AB6-A6723A95388CQ28237144-7A885694-EC38-40F4-975E-DDE519554338Q28344127-78B12BF8-88B4-4D1D-8FA4-989C4C51D554Q33664128-557868AF-C642-47B9-936C-7837F45BF33CQ33922712-0D753190-D27D-41A1-A8BF-61DF0257786FQ33936573-64DF3891-9A23-4CA2-8509-6F706BA6B24FQ33982922-8A67398D-9094-484A-82D1-A3626AC9F93CQ34019379-0CAF6D38-00EC-4EB3-94C3-8BB7CB096A74Q34090583-3AE2163F-9F8B-41C4-A0C1-6C6D743A26CDQ34123652-AB15BF67-8F92-4712-AA6C-98354AAE0440Q34154939-6EB70452-2028-4047-8222-F05EC669189DQ34188511-95C25049-89F1-4DCB-9A80-8A935BC41B42Q34401549-FF956839-B250-46CD-9275-A3ADB23F98A4Q34558112-9B821798-E5A9-4211-8366-010C214EB486Q34624505-F98BB85F-78B6-4B5B-A8EE-617CE69C2750Q34941977-89F6B06B-D85C-4492-B760-4D3FADBDA467Q35102211-0F0D13CF-0CB4-4F7B-B1F9-D008DD01468AQ35803786-ED35BB9C-D41C-49AD-B033-C6A9FA5474FFQ35826938-C75CC3C6-7B77-4759-9238-17B4FB6162EAQ36018001-332E0AA7-2CAC-4C29-9FA0-B8DC39C78023Q36609716-0462ADB6-6F59-4120-AA9E-FC0B3D1BCDFAQ37486720-CAF50D52-04F7-4871-9C01-F030B75230F6Q37806982-3B33BA71-B7E0-48F4-9739-249FC232ED5AQ37954366-71CA8F45-25EC-4ACA-A8BC-48FF39E87D59Q38178326-4B2BA0D4-CC8A-4924-A497-27137B7C16DFQ38513684-59750764-67E5-4363-98ED-F403D9D21519Q38803195-696AE1BE-1EC6-4071-AD5D-AE1F7185A2B0Q40379431-2C268CD1-F2D3-4184-B5FD-094C9FB99922Q40575037-5A4ADD00-8146-4E0C-A89A-FD2CA9F1791BQ41631036-CEB3ED92-8B0C-4387-B6F8-2476D9FCABA0Q42098029-4B373706-A566-4E4B-B1BA-576D40E1E6E0Q42985589-76EFD37E-1C8C-4926-9E4E-673739CCD210Q44160222-F9AE84AA-8FCA-4BA6-9AAD-3550CB99A78AQ44649926-2169213A-2260-4108-9982-F89EE1D3FBC0Q45759815-16423F34-5499-4FDA-A5BC-23C600B7F492Q46766394-F5A22227-8FED-44C7-842C-D311B6F71C41Q47237324-6DA3A1A4-4EAF-419D-B194-21FDBB27D4FCQ51939394-AC99EF2F-0C4C-4A59-8480-4A6423EFF415Q53635482-61F0C339-9366-4B47-8C3E-108E2F127620
P2860
The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
1998年论文
@zh
1998年论文
@zh-cn
name
The effects of genetic polymor ...... d population pharmacokinetics.
@en
The effects of genetic polymor ...... d population pharmacokinetics.
@nl
type
label
The effects of genetic polymor ...... d population pharmacokinetics.
@en
The effects of genetic polymor ...... d population pharmacokinetics.
@nl
prefLabel
The effects of genetic polymor ...... d population pharmacokinetics.
@en
The effects of genetic polymor ...... d population pharmacokinetics.
@nl
P2093
P2860
P1433
P1476
The effects of genetic polymor ...... d population pharmacokinetics.
@en
P2093
H Ninomiya
J Shimamoto
P2860
P304
P356
10.1111/J.1528-1157.1998.TB01330.X
P577
1998-12-01T00:00:00Z